Hoth Therapeutics releases December 2024 corporate presentation highlighting pipeline and milestones

Hoth Therapeutics, Inc.

HT-001 Phase 2a for EGFR inhibitor skin toxicity: all sites active, enrolling open-label and double-blind; interim PK data expected Q1 2025.
HT-KIT: pre-IND meeting with FDA successful; IND-enabling tox studies ongoing; IND submission target Q4 2025.
HT-ALZ: US patent awarded Q3 2024; preclinical studies completed at WashU; pre-IND meeting planned for 2025.
BioLexa Phase 1b data readout completed in 2023; proof-of-concept results shown; non-corticosteroid treatment for atopic dermatitis.
7.7M shares outstanding as of Nov 29, 2024; cash on hand sufficient to fund current clinical and preclinical programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.